开发用于治疗他莫昔芬耐药性乳腺癌的新型雌激素受体靶向治疗药物。
Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.
机构信息
Department of Chemistry, Xavier University of Louisiana, New Orleans, LA 70125, USA.
出版信息
Future Med Chem. 2013 Jun;5(9):1023-35. doi: 10.4155/fmc.13.63.
Abstract
Despite our deepening understanding of the mechanisms of resistance and intensive efforts to develop therapeutic solutions to combat resistance, de novo and acquired tamoxifen resistance remains a clinical challenge, and few effective regimens exist to treat tamoxifen-resistant breast cancer. The complexity of tamoxifen resistance calls for diverse therapeutic approaches. This review presents several therapeutic strategies and lead compounds targeting the estrogen receptor signaling pathways for treatment of tamoxifen-resistant breast cancer, with a critical assessment of challenges and potentials regarding clinical outcome. Medicinal chemistry holds the key to effective, personalized combination therapy for tamoxifen-resistant breast cancer by making available a diverse arsenal of small-molecule drugs that specifically target signaling pathways modulating hormone resistance. These combination therapy candidates should have the desired specificity, selectivity and low toxicity to resensitize tumor response to tamoxifen and/or inhibit the growth and proliferation of resistant breast cancer cells.
摘要
尽管我们对耐药机制的理解不断加深，并且为了寻找治疗耐药的方法付出了巨大努力，但新出现的和获得性的他莫昔芬耐药仍然是一个临床挑战，并且几乎没有有效的方案可以治疗他莫昔芬耐药的乳腺癌。他莫昔芬耐药的复杂性需要多种治疗方法。这篇综述介绍了几种针对雌激素受体信号通路的治疗策略和先导化合物，用于治疗他莫昔芬耐药的乳腺癌，并对临床结果的挑战和潜力进行了批判性评估。通过提供针对调节激素耐药的信号通路的多样化小分子药物，药物化学为有效的、个性化的他莫昔芬耐药乳腺癌联合治疗提供了关键，这些联合治疗候选药物应该具有所需的特异性、选择性和低毒性，以重新使肿瘤对他莫昔芬敏感和/或抑制耐药乳腺癌细胞的生长和增殖。
相似文献
1
Development of new estrogen receptor-targeting therapeutic agents for tamoxifen-resistant breast cancer.开发用于治疗他莫昔芬耐药性乳腺癌的新型雌激素受体靶向治疗药物。
Future Med Chem. 2013 Jun;5(9):1023-35. doi: 10.4155/fmc.13.63.
2
Aromatase and breast cancer.芳香化酶与乳腺癌
J Steroid Biochem Mol Biol. 2006 Dec;102(1-5):97-102. doi: 10.1016/j.jsbmb.2006.09.002.
3
Sex steroid induced apoptosis as a rational strategy to treat anti-hormone resistant breast and prostate cancer.性类固醇诱导的细胞凋亡作为治疗抗激素耐药性乳腺癌和前列腺癌的合理策略。
Discov Med. 2016 May;21(117):411-27.
4
Hormonal therapy of breast cancer.
Cancer Treat Rev. 1998 Jun;24(3):221-40. doi: 10.1016/s0305-7372(98)90051-2.
5
Epidermal growth factor receptor/HER2/insulin-like growth factor receptor signalling and oestrogen receptor activity in clinical breast cancer.临床乳腺癌中表皮生长因子受体/人表皮生长因子受体2/胰岛素样生长因子受体信号传导与雌激素受体活性
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S99-S111. doi: 10.1677/erc.1.01005.
6
Mechanisms of tamoxifen resistance in the treatment of advanced breast cancer.他莫昔芬治疗晚期乳腺癌的耐药机制。
Acta Oncol. 1996;35 Suppl 5:9-14. doi: 10.3109/02841869609083961.
7
Growth factor signalling and response to endocrine therapy: the Royal Marsden Experience.生长因子信号传导与内分泌治疗反应：皇家马斯登医院的经验
Endocr Relat Cancer. 2005 Jul;12 Suppl 1:S113-7. doi: 10.1677/erc.1.01044.
8
Pathways to tamoxifen resistance.他莫昔芬耐药的途径。
Cancer Lett. 2007 Oct 18;256(1):1-24. doi: 10.1016/j.canlet.2007.03.016. Epub 2007 May 1.
9
Mechanisms of tamoxifen resistance.他莫昔芬耐药的机制。
Endocr Relat Cancer. 2004 Dec;11(4):643-58. doi: 10.1677/erc.1.00776.
10
Tamoxifen ("Nolvadex"): a review.他莫昔芬（“诺瓦得士”）：综述
Cancer Treat Rev. 2002 Aug;28(4):165-80. doi: 10.1016/s0305-7372(02)00036-1.
引用本文的文献
1
MiR-592 Attenuates Tamoxifen Resistance in Breast Cancer Through PIK3CA-Mediated PI3K/AKT/mTOR Signaling Pathway.微小RNA-592通过PIK3CA介导的PI3K/AKT/mTOR信号通路减轻乳腺癌中的他莫昔芬耐药性。
Appl Biochem Biotechnol. 2025 Mar;197(3):2051-2065. doi: 10.1007/s12010-024-05123-x. Epub 2024 Dec 11.
2
IONIC NANOMEDICINE STRATEGY TO DEVELOP EFFECTIVE CHEMO-PTT COMBINATION CANCER THERAPEUTICS.开发有效的化疗-光热疗法联合癌症治疗方法的离子纳米医学策略
World J Pharm Sci Res. 2024 Oct;3(5):454-478. doi: 10.5281/zenodo.14146024.
3
Knockdown circTRIM28 enhances tamoxifen sensitivity via the miR-409-3p/HMGA2 axis in breast cancer.敲低 circTRIM28 通过 miR-409-3p/HMGA2 轴增强乳腺癌对他莫昔芬的敏感性。
Reprod Biol Endocrinol. 2022 Sep 30;20(1):146. doi: 10.1186/s12958-022-01011-3.
4
Recent progress in selective estrogen receptor downregulators (SERDs) for the treatment of breast cancer.用于治疗乳腺癌的选择性雌激素受体下调剂（SERDs）的最新进展。
RSC Med Chem. 2020 Mar 6;11(4):438-454. doi: 10.1039/c9md00570f. eCollection 2020 Apr 1.
5
TCRP1 induces tamoxifen resistance by promoting the activation of SGK1 in MCF‑7 cells.TCRP1 通过促进 MCF-7 细胞中 SGK1 的激活来诱导他莫昔芬耐药性。
Oncol Rep. 2020 Jun;43(6):2017-2027. doi: 10.3892/or.2020.7577. Epub 2020 Apr 3.
6
circRNA_0025202 Regulates Tamoxifen Sensitivity and Tumor Progression via Regulating the miR-182-5p/FOXO3a Axis in Breast Cancer.环状 RNA_0025202 通过调控 miR-182-5p/FOXO3a 轴调控乳腺癌他莫昔芬敏感性和肿瘤进展。
Mol Ther. 2019 Sep 4;27(9):1638-1652. doi: 10.1016/j.ymthe.2019.05.011. Epub 2019 May 17.
7
Preparation of anastrozole loaded PEG-PLA nanoparticles: evaluation of apoptotic response of breast cancer cell lines.阿那曲唑负载聚乙二醇-聚乳酸纳米粒的制备：乳腺癌细胞系凋亡反应的评估
Int J Nanomedicine. 2017 Dec 28;13:199-208. doi: 10.2147/IJN.S151139. eCollection 2018.
8
A transgenic mouse model expressing an ERα folding biosensor reveals the effects of Bisphenol A on estrogen receptor signaling.一种表达 ERα 折叠生物传感器的转基因小鼠模型揭示了双酚 A 对雌激素受体信号的影响。
Sci Rep. 2016 Oct 10;6:34788. doi: 10.1038/srep34788.
9
Fulvestrant-3 Boronic Acid (ZB716): An Orally Bioavailable Selective Estrogen Receptor Downregulator (SERD).氟维司群-3硼酸（ZB716）：一种口服生物可利用的选择性雌激素受体下调剂（SERD）。
J Med Chem. 2016 Sep 8;59(17):8134-40. doi: 10.1021/acs.jmedchem.6b00753. Epub 2016 Aug 29.
10
Artonin E and Structural Analogs from Artocarpus Species Abrogates Estrogen Receptor Signaling in Breast Cancer.面包果属植物中的阿尔托宁E及其结构类似物可消除乳腺癌中的雌激素受体信号传导。
Molecules. 2016 Jun 29;21(7):839. doi: 10.3390/molecules21070839.
本文引用的文献
1
The Effect of Selective Estrogen Receptor Modulators (SERMs) on the Tamoxifen Resistant Breast Cancer Cells.选择性雌激素受体调节剂（SERMs）对他莫昔芬耐药乳腺癌细胞的影响。
Toxicol Res. 2011 Jun;27(2):85-93. doi: 10.5487/TR.2011.27.2.085.
2
Boron-Based 4-Hydroxytamoxifen Bioisosteres for Treatment of de Novo Tamoxifen Resistant Breast Cancer.用于治疗原发性他莫昔芬耐药乳腺癌的硼基4-羟基他莫昔芬生物电子等排体
ACS Med Chem Lett. 2012 Apr 6;3(5):392-396. doi: 10.1021/ml3000287.
3
Novel aromatase inhibitors by structure-guided design.基于结构导向设计的新型芳香酶抑制剂。
J Med Chem. 2012 Oct 11;55(19):8464-76. doi: 10.1021/jm300930n. Epub 2012 Sep 24.
4
Adjuvant endocrine therapy for breast cancer.乳腺癌的辅助内分泌治疗。
Oncology (Williston Park). 2012 Jun;26(6):541-7, 550, 552 passim.
5
Randomized phase II study of three doses of oral TAS-108 in postmenopausal patients with metastatic breast cancer.一项在绝经后转移性乳腺癌患者中进行的口服 TAS-108 三种剂量的随机 II 期研究。
Cancer Sci. 2012 Sep;103(9):1708-13. doi: 10.1111/j.1349-7006.2012.02354.x. Epub 2012 Jul 16.
6
Randomized phase II trial of everolimus in combination with tamoxifen in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer with prior exposure to aromatase inhibitors: a GINECO study.随机 II 期试验：依维莫司联合他莫昔芬治疗激素受体阳性、人表皮生长因子受体 2 阴性、既往接受过芳香化酶抑制剂治疗的转移性乳腺癌患者：GINECO 研究。
J Clin Oncol. 2012 Aug 1;30(22):2718-24. doi: 10.1200/JCO.2011.39.0708. Epub 2012 May 7.
7
Rhodacyanine derivative selectively targets cancer cells and overcomes tamoxifen resistance.吖啶酮衍生物选择性靶向癌细胞并克服他莫昔芬耐药性。
PLoS One. 2012;7(4):e35566. doi: 10.1371/journal.pone.0035566. Epub 2012 Apr 26.
8
Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer.依维莫司用于绝经后激素受体阳性的晚期乳腺癌。
N Engl J Med. 2012 Feb 9;366(6):520-9. doi: 10.1056/NEJMoa1109653. Epub 2011 Dec 7.
9
Breast and cervical cancer in 187 countries between 1980 and 2010: a systematic analysis.1980 年至 2010 年 187 个国家的乳腺癌和宫颈癌：系统分析。
Lancet. 2011 Oct 22;378(9801):1461-84. doi: 10.1016/S0140-6736(11)61351-2. Epub 2011 Sep 14.
10
A phase II study of the histone deacetylase inhibitor vorinostat combined with tamoxifen for the treatment of patients with hormone therapy-resistant breast cancer.一项评估组蛋白去乙酰化酶抑制剂伏立诺他联合他莫昔芬治疗激素治疗抵抗性乳腺癌患者的 II 期临床研究。
Br J Cancer. 2011 Jun 7;104(12):1828-35. doi: 10.1038/bjc.2011.156. Epub 2011 May 10.
Zotero 插件